Aim of the survey
The aim of the survey is to identify needs and priorities of academic stakeholders involved in clinical trials, integrating them into the work of ACT EU. It seeks to address challenges in conducting clinical trials in the EU faced by ERNs and academics, highlight topics needing further clarification or discussion, and propose solutions for improving and accelerating clinical trials.  Academic stakeholders are encouraged to contribute ideas for improvement across various aspects of clinical trial governance and implementation, clinical trial methodologies and data analytics, regulatory processes, safety monitoring, training, and emergency preparedness.

What is ACT EU?
The ACT EU (Accelerated Clinical Trials in Europe) initiative is a collaboration between EMA, the Heads of Medicines Agencies (HMA) and the European Commission (EC), which seeks to transform how clinical trials are initiated, designed, and run. It encompasses a range of priority actions which aim to foster collaboration, streamline processes, and improve the regulatory environment to facilitate the conduct of clinical trials in the EU, ultimately benefiting patients and advancing medical research and innovation.

Survey summary

Survey ACT-EU Survey
Target Academic Stakeholders
Deadline 30 June 2024
More information
 ACT EU workplan